Navigation Links
Headaches in Medical Technology

For Iraq Veterans, Headaches Continue After Traumatic Brain Injury

... Nearly 98 percent of the soldiers reported having headaches during the last three months of their deployment. The headaches started within one week of the traumatic brain ... weeks for 20 percent. Among the soldiers whose headaches started within a week of the injury, 60 percent ...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

... diagnosed with migraine headaches. Acute migraine headaches occur often, usually one to four times a month. ... for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute ...

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

... for the treatment of migraine headaches." About Acute Migraine headaches According to the National Headache Foundation, approximately 13 ... United States have been diagnosed with migraine headaches. Acute migraine headaches occur often, usually one to four times a month. Of the estimated 29.5 ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting

... developments of the last 50 years -- including the top five advances in headaches -- and what researchers envision for the future. For additional ... unknown role certain brain cells play in triggering chronic headaches for 9 million Americans Think that pain medication is helping you ...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine

... month with Treximet. Migraines Impact Millions of Americans Migraine headaches continue to be a significant problem for the estimated 29.5 million ... Society's diagnostic criteria, migraine is characterized by recurrent headaches which, if untreated, typically last four to 72 hours, with symptoms ...

Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status

... AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks ...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

... , women's health , surgery and the surgical subspecialties . Montefiore is a national leader in the research and treatment of diabetes, headaches , obesity, cough and sleep disorders , geriatrics and geriatric psychiatry , neurology and neurosurgery , adolescent and family ...

Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)

... back. The lessons also reverse long-standing movement habits often responsible for the original TMJ symptoms. TMJ-related problems such as headaches and grinding teeth (bruxism) have been on the rise as the current economic downturn causes increased stress in people. These problems, while often ...

March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots

... easily, trouble falling or staying asleep, difficulty concentrating, fatigue, muscle tension, restlessness, feeling out of breath, nausea, diarrhea, headaches and excessive irritability. Signs and symptoms appear gradually over time. Some who have GAD cannot recall the last time they felt at ease. ...

Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009

... Program, Poster 261 Public Opinion Survey Regarding Prescription Pain Medication, Poster 266 Prevalence of Chronic Pain, Poster 272 headaches in Iraq/Afghanistan Veterans & Trauma/Combat Injury, Poster 273 Reduction of Opioid/Illicit Drug Abuse & Electronic Prescription ...

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

... the most commonly reported adverse drug reaction, occurring in 35 percent of patients receiving Nplate and 32 percent of patients receiving placebo. headaches were usually of mild or moderate severity. -- Most common adverse reactions (greater than or equal to 5 percent higher patient incidence in ...

September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging

... ROCHESTER, Minn. -- Severe and frequent headaches, especially in people who don't typically have headaches, warrant a visit to the doctor. The headaches could be a symptom of vasculitis -- blood vessel inflammation. Vasculitis is an autoimmune disease, where the body's immune system mistakenly attacks ...

MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

... the slow onset of action, short duration of effect, inconsistent response, unacceptable side effect profiles, or propensity to increase frequency of headaches with these therapies. In 2007, triptans, the class of drugs most often prescribed for treating migraine, generated sales of approximately $2.2 ...

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

... the slow onset of action, short duration of effect, inconsistent response, unacceptable side effect profiles, or propensity to increase frequency of headaches with these therapies. In 2007, triptans, the class of drugs most often prescribed for treating migraine, generated sales of approximately $2.2 ...

Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease

... (16%). The most common adverse event in the Dimebon group was headache, which occurred in 19% of treated patients compared to 7% of placebo patients. headaches were generally mild in severity. Dry mouth and depressed mood were similar in both treated and placebo groups (4% and 7%, respectively). "To my ...

MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting

... the slow onset of action, short duration of effect, inconsistent response, unacceptable side effect profiles, or propensity to increase frequency of headaches with these therapies. About MAP Pharmaceuticals, Inc. MAP Pharmaceuticals develops and plans to commercialize new therapies for children and ...

NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression

... medication or talk therapy. In addition, antidepressant medications often come with troubling side effects, such as sleep changes, sexual problems, headaches and gastrointestinal problems, and an analysis by the Food and Drug Administration has shown that antidepressants may cause suicidal thinking and ...

Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients

... treatment with 200 or 500 mg of PS433540 was well tolerated. Most of the adverse events reported were mild or moderate in severity and included headaches and minor musculoskeletal and respiratory complaints. All of these events occurred with similar frequency in the three treatment groups. There was ...

Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients

... to the National Headache Foundation, approximately 13 million people in the United States have been diagnosed with migraine headaches. Acute migraine headaches occur often, usually one to four times a month. Of the estimated 29.5 million migraine sufferers (including diagnosed and undiagnosed sufferers), ...

New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol

... questions about sexual performance. LEVITRA was well tolerated. Treatment-emergent adverse effects (occurring in = 5% of patients) included headaches (9% for LEVITRA, 1% for placebo) and upper respiratory tract infections (5% for LEVITRA, 3% for placebo). Background: Erectile dysfunction ...

Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia

... site reactions were more common among VAPRISOL-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for VAPRISOL 20mg/day and 40mg/day, respectively. ...

Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference

... in Phase II trials for hematologic malignancies. The most common toxicities observed were fatigue, vomiting, anorexia, diarrhea, nausea, headaches and decreased hemoglobin (anemia), all of which were less than or equal to grade 3. In addition, grade 4 hyperkalemia and thrombocytopenia were ...

Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache

... an additional route of administration to potentially address the varied and unmet needs of migraine and pain sufferers. About Acute Migraine headaches Migraine is a debilitating neurological condition characterized by an intense and disabling episodic headache. According to the National ...

Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia

... site reactions were more common among VAPRISOL-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for VAPRISOL 20mg/day and 40mg/day, respectively. ...

Aspirin Named 8th World Wonder by Majority of Americans

... for mankind." Aspirin was also close at hand during the 1993 Mount Everest expedition with climbers depending upon aspirin to provide relief from headaches at high altitudes. Aspirin was initially developed in 1897 as a relief for arthritis. Today, aspirin is relied upon by millions for the treatment of ...

Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study

... female (89 percent) with an average age of 41 years. Most treated headaches were moderate in baseline severity and did not have aura. The first ... U.S. Food and Drug Administration in 2009. About migraines Migraine headaches impact approximately 28 million Americans, primarily women. Unlike a bad ...

Ace Biosciences, Ace393, the World's First Commercial Vaccine for Travellers' Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

... administered in two doses either two or three weeks apart, with 100% of subjects responding. Adverse reactions were transient local site reaction and headaches in some subjects. Dr Philippe Reboud, (Mediscis Phase I clinical unit) the study_s Principal Investigator commented "These are very ...

Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine

... three strain A/Hong Kong/156/97, and the Clade two strain A/Indonesia/05/05. The most common side effects observed were injection site reactions, headaches and fatigue. The minimal occurrence and low level of side effects are similar to those reported for licensed egg-based, seasonal influenza vaccines. ...

Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments

... 55 % 70 % 12 % Forgetfulness 52 % 55 % 7 % Rebound headaches 52 % 74 % 24 % Eighty percent of physicians surveyed said they are "very" or "somewhat" satisfied with ...

NovaDel Announces Positive Data from Two Studies Comparing Zolpidem Oral Spray to Ambien Tablets

... array of existing and future pharmaceutical products. The Company's most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system. NovaDel plans to develop these and other products independently and through collaborative arrangements ...

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

... death were similar in the treated and placebo groups. The most frequent adverse events (as categorized by common terms) were diarrhea, headaches and nausea. About Eprodisate (KIACTA(TM)) Eprodisate (KIACTA(TM)) was investigated in a landmark international, randomized, double-blind, ...
Other Contents
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
(Date:7/31/2015)... julho de 2015 A 10 a. ... realizada pela BGI de 22-25 de outubro de 2015, em ... A conferência está celebrando seu 10 o. aniversário este ... tornou uma das reuniões mais influentes do mundo no ... dinâmicos, entusiastas e prazerosos. A ICG-10 ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
(Date:8/31/2015)... ... , ... On Saturday, May 30th, 2015, Best Drug Rehabilitation sponsored a benefit ... IL. The purpose behind this concert was to raise money for music education programs ... Rehabilitation’s sponsorship of “Music with a Mission” helped with a portion of the cost ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... e-Spirit to future-proof its content management system (CMS) and make website updates quicker ... Sports in making the websites of the Bundesliga (the German equivalent of the ...
(Date:8/31/2015)... Pittsburgh, PA (PRWEB) , ... August 31, 2015 , ... ... their ears,” said an inventor, from Hagerhill, Ky. “I thought there could be a ... Cannula Ear Protector. , The Nasal Cannula Ear Protector offers a more secure way ...
(Date:8/31/2015)... YORK (PRWEB) , ... August 31, 2015 , ... Move ... anti-aging products for men and barbershops are scrambling to meet it. , Reports published ... information for hairstyles and haircare. But the data also reflects that men are getting ...
(Date:8/31/2015)... Tennessee (PRWEB) , ... August ... ... of Lifestyle Medicine (ACLM), the nation’s medical professional association for physicians and ... in conjunction with the Lifestyle Medicine Foundation, announced today the establishment of ...
Breaking Medicine News(10 mins):Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3
Other TagsOther Tags